ZGGS 001
Alternative Names: ZGGS-001Latest Information Update: 06 Jan 2023
At a glance
- Originator Suzhou Zelgen Biopharmaceuticals
- Class Antineoplastics; Trispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 Dec 2022 Preclinical trials in Solid tumours in China (Parenteral) before December 2022 (Suzhou Zelgen Biopharmaceuticals pipeline, December 2022)